130 related articles for article (PubMed ID: 31692117)
1. Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
Diabet Med; 2020 Apr; 37(4):648-656. PubMed ID: 31692117
[TBL] [Abstract][Full Text] [Related]
2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
[TBL] [Abstract][Full Text] [Related]
4. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
[TBL] [Abstract][Full Text] [Related]
5. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
8. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
9. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
10. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
11. Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.
van Gorp AM; Rolfes L; Härmark L; van der Horst P; Hendriks J; Vorstenbosch S
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1588-1595. PubMed ID: 32854158
[TBL] [Abstract][Full Text] [Related]
12. Changes in the use of glucose-lowering drugs: A Danish nationwide study.
Pottegård A; Andersen JH; Søndergaard J; Thomsen RW; Vilsbøll T
Diabetes Obes Metab; 2023 Apr; 25(4):1002-1010. PubMed ID: 36514856
[TBL] [Abstract][Full Text] [Related]
13. Adverse Effects Associated With Newer Diabetes Therapies.
Akiyode OF; Adesoye AA
J Pharm Pract; 2017 Apr; 30(2):238-244. PubMed ID: 26169212
[TBL] [Abstract][Full Text] [Related]
14. Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups.
Csatordai M; Benkő R; Matuz M; Bor A; Lengyel C; Doró P
Diabet Med; 2019 Dec; 36(12):1612-1620. PubMed ID: 31456231
[TBL] [Abstract][Full Text] [Related]
15. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
Packer M
Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
[TBL] [Abstract][Full Text] [Related]
16. Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
Pasternak B; Wintzell V; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Svanström H; Ueda P
Diabetes Care; 2020 Jun; 43(6):1326-1335. PubMed ID: 32295809
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
[TBL] [Abstract][Full Text] [Related]
18. Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.
Lau KTK; Wong CKH; Au ICH; Lau WCY; Man KKC; Chui CSL; Wong ICK
J Am Heart Assoc; 2022 Apr; 11(7):e023489. PubMed ID: 35322676
[TBL] [Abstract][Full Text] [Related]
19. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
20. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
